Session » (1977–1995) Osteoarthritis – Clinical Poster III

Date: Tuesday, November 14, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

Abstract Number: 1977

Combined Datasets for CNTX-4975 Osteoarthritis Knee Pain (OAKP) Phase 3 Trials (OAKP 301 and 304) to Assess Overall Efficacy and Safety of an Intra-articular Injection (IAI) of CNTX-4975-05 (CNTX) in Subjects with Chronic, Moderate-to-severe Osteoarthritis Knee Pain (MSOAKP)

Abstract Number: 1978

Infrapatellar Fat Pad Size and Subcutaneous Fat in Knee Osteoarthritis Radiographic Progression: Data from the Osteoarthritis Initiative

Abstract Number: 1979

Weight Loss Induced by Anti-obesity Medications and All-cause Mortality Among Patients with Knee or Hip Osteoarthritis

Abstract Number: 1980

Movement Evoked Pain as an Outcome Measure in Patients with Knee Osteoarthritis

Abstract Number: 1981

The Association Between X-ray Progression and Clinical Outcomes in Patients with Hand Osteoarthritis with 5-year Follow-up

Abstract Number: 1982

Effect of Denosumab on Knee Pain and Bone Marrow Lesions in Symptomatic Knee Osteoarthritis

Abstract Number: 1983

Heated Mittens for Patients with Hand Osteoarthritis: A Randomized Trial

Abstract Number: 1984

Therapeutic Effects of Pentosan Polysulfate Sodium on Clinical and Disease Modifying Outcomes in Subjects with Knee Osteoarthritis

Abstract Number: 1985

Preliminary Results for the Total Knee Replacement Coaching Program for Patients Preparing to Undergo Total Knee Arthroplasty, a Pilot Randomized Trial

Abstract Number: 1986

Deep Immunophenotyping of Osteoarthritis Patients Demonstrates Baseline Alterations in Monocyte Populations in OA, Dendritic Cell Subpopulations Among Radiographic Progressors, and Th17 Cells Among Pain Progressors

Abstract Number: 1987

Clinical and Imaging Characteristics of Individuals Who Underwent Knee Replacement During Years 3 to 5 in the FORWARD Study: A Post Hoc Analysis

Abstract Number: 1988

Extended-Release versus Immediate-Release Triamcinolone Acetonide for Osteoarthritis of the Knee with Comorbid Diabetes Type 2 Diabetes Mellitus: A Post Hoc Analysis

Abstract Number: 1989

Shared Variation Among Cartilage Thickness Change Maps and Baseline Clinical Features at the Initiation of Structural Knee Osteoarthritis

Abstract Number: 1990

Effects of Exercise on Movement-Evoked Pain in People with Knee Osteoarthritis

Abstract Number: 1991

Therapeutic Efficacy of Intra Articular Injection of Human Bone Marrow Derived Mesenchymal Stem Cells in Knee Osteoarthritis; Randomized, Double-blind, Placebo-controlled Clinical Trial

Abstract Number: 1992

Association Between Knee Osteoarthritis Pain and Concomitant Drug Use: A Post-hoc Analysis of Two Phase 3 Clinical Trials

Abstract Number: 1993

Impact of Metabolic Syndrome on Ultrasonographic Findings and Quality of Life in Patients with Early Osteoarthritis

Abstract Number: 1994

How Is Paracetamol Prescribed in Low Back Pain and Osteoarthritis in France? Paracetamol Prescription Patterns in the Real-World General Practice

Abstract Number: 1995

Cross-cultural Adaptation, Reduction, and Validation of the Turkish Versions of the Flare-OA Questionnaire for Hip and Knee Osteoarthritis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.